Inhibitor of tissue-type and urokinase-type plasminogen activators
AssigneeScripps Clinic and Research Foundation
InventorsDavid J. Loskutoff, Tor Ny, Michael Sawdey
Life of this patent
Estimating the term…
Abstract
A biological reagent and diagnostic system for the detection and quantitation of endothelial plasminogen activator inhibitor (PAI) are disclosed, as are substantially pure, recombinant human endothelial PAI, its biologically pure gene and a vector for cloning the gene and expressing a gene product.
Claims3
Substantially pure recombinant, human endothelial plasminogen activator inhibitor having the amino acid residue sequence of FIG. 22 from amino acid residue position 1 through position 379, said inhibitor inhibiting the activities of both t-PA and u-PA and being a fusion polypeptide that exhibits an apparent relative molecular mass of about 180 kilodaltons in SDS-PAGE analysis.
Substantially pure recombinant, human endothelial plasminogen activator inhibitor having the amino acid residue sequence of FIG. 22 from amino acid residue position 1 through position 379, said inhibitor inhibiting the activities of both t-PA and u-PA, and exhibiting an apparent relative molecular mass of about 40 kilodaltons in SDS-PAGE analysis.
Substantially pure recombinant, human endothelial plasminogen activator inhibitor having the amino acid residue sequence of FIG. 22 from amino acid residue position 1 through position 379, said inhibitor being substantially free of glycosylation and inhibiting the activities of both t-PA and u-PA.
Dependencies are inferred from the claim text.